Parallel Declines in HPV6/11-Related Disease Incidences: A National Study of Anogenital Warts and Recurrent Respiratory Papillomatosis in Norway

Clicks: 5
ID: 322927
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #66 of 207 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 207 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Anogenital Warts (AGW) and Recurrent Respiratory Papillomatosis (RRP) are conditions caused by Human Papillomavirus (HPV) types 6/11 that can be prevented by vaccination. We analyzed Norwegian national registry data (2010-2023) to assess the impact of the 4-valent HPV vaccine introduced in 2009. AGW incidence among females aged 15-29 decreased significantly from 1,120.0 to 280.6 per 100,000 (APC: -10.3%), paralleling a sharp decline in RRP from 3.7 to 0.6 per 100,000 (APC: -11.3%). These results strongly support vaccination impact in reducing the burden of HPV 6/11-related diseases, suggesting successful interruption of transmission pathways and substantial population-level protection.
Reference Key
openalex_W7171673644 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Madleen Orumaa, Ståle Nygård, Joseph Tota, Parag Mahale, Thea E. Hetland Falkenthal
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag456
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.